Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TRVI

Trevi Therapeutics Inc

Dec 13 • 03:45PM ET

4.14

Dollar change +0.54
Percentage change 15.00	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AMGN ABBV LLY REGN BIIB GILD NBIX VRTX BMRN

| Held by: IWM VTI VXF IWO IWN VTWO IWC AVSC RSSL VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.44	Insider Own	40.68%	Shs Outstand	75.45M	Perf Week	50.00%
Market Cap	318.23M	Forward P/E	-	EPS next Y	-0.49	Insider Trans	-0.36%	Shs Float	45.60M	Perf Month	44.76%
Income	-44.32M	PEG	-	EPS next Q	-0.12	Inst Own	41.08%	Short Float	3.10%	Perf Quarter	17.95%
Sales	0.00M	P/S	-	EPS this Y	-67.59%	Inst Trans	8.78%	Short Ratio	0.93	Perf Half Y	56.23%
Book/sh	0.78	P/B	5.30	EPS next Y	-1.85%	ROA	-53.78%	Short Interest	1.41M	Perf Year	225.98%
Cash/sh	0.85	P/C	4.86	EPS next 5Y	-	ROE	-59.65%	52W Range	1.22 - 4.60	Perf YTD	208.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.24%	ROI	-74.13%	52W High	-10.00%	Beta	0.95
Dividend TTM	-	Quick Ratio	7.38	Sales past 5Y	0.00%	Gross Margin	-	52W Low	239.34%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	7.38	EPS Y/Y TTM	-62.86%	Oper. Margin	-	RSI (14)	73.64	Volatility	15.03% 8.56%
Employees	25	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.10	Target Price	9.15
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-68.65%	Payout	-	Rel Volume	2.68	Prev Close	3.60
Sales Surprise	-	EPS Surprise	-8.79%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	1.52M	Price	4.14
SMA20	43.63%	SMA50	38.31%	SMA200	40.73%	Trades		Volume	3,913,736	Change	15.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-24	Reiterated	H.C. Wainwright	Buy	$6 → $7.50
Sep-09-24	Resumed	Leerink Partners	Outperform	$6 → $7
Aug-30-24	Initiated	Raymond James	Outperform	$9
Aug-30-24	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-12-23	Initiated	B. Riley Securities	Buy	$6
Nov-22-22	Initiated	SVB Leerink	Outperform	$6
Jun-03-19	Initiated	SVB Leerink	Outperform	$14
Jun-03-19	Initiated	Stifel	Buy	$20
Jun-03-19	Initiated	Needham	Buy	$18
Jun-03-19	Initiated	BMO Capital Markets	Outperform	$15

Show Previous Ratings

Today 07:10AM	Trevis chronic cough trial in IPF subjects continues without sample size change (Clinical Trials Arena) +15.00%
Dec-12-24 09:47AM	Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? (Benzinga) +44.58%
07:30AM	Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough (PR Newswire)
Dec-03-24 04:05PM	Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine (PR Newswire) -6.47%
Nov-21-24 07:30AM	Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
01:18PM	Loading…
Nov-07-24 01:18PM	Q3 2024 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.45%
02:21AM	Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... (GuruFocus.com)
Nov-06-24 04:05PM	Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (PR Newswire)
Oct-30-24 04:05PM	Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 (PR Newswire)
Oct-23-24 05:02PM	Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc. (GuruFocus.com)
Oct-21-24 07:30AM	Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough (PR Newswire) +7.37%
Oct-15-24 07:30AM	Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences (PR Newswire)
Oct-09-24 05:58PM	Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -5.08%
Oct-03-24 04:05PM	Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program (PR Newswire) -5.33%
Sep-30-24 05:30PM	Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer (PR Newswire) -6.89%
07:30AM	Loading…
Sep-26-24 07:30AM	Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 (PR Newswire)
Sep-04-24 04:05PM	Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 (PR Newswire) +5.08%
Aug-30-24 09:33AM	Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls (The Fly) +8.59%
Aug-28-24 07:30AM	Trevi Therapeutics to Participate in September Investor and Medical Conferences (PR Newswire)
Aug-08-24 09:58PM	TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024 (InvestorPlace) +8.11%
04:05PM	Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance (PR Newswire)
Aug-01-24 07:30AM	Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 (PR Newswire)
Jul-02-24 07:30AM	Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events (PR Newswire) -7.27%
May-13-24 08:57AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:30AM	Trevi Therapeutics to Participate in Upcoming Conferences (PR Newswire) +10.61%
May-08-24 06:56AM	Q1 2024 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -8.97%
May-07-24 08:59PM	TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
06:25PM	Trevi Therapeutics Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
04:05PM	Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (PR Newswire)
May-01-24 04:05PM	Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 (PR Newswire) +5.24%
09:55AM	Loading…
Apr-18-24 09:55AM	Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-09-24 07:30AM	Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference (PR Newswire) -8.13%
Apr-04-24 08:30AM	Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick (Zacks)
07:30AM	Trevi Therapeutics to Participate in Upcoming April Events (PR Newswire)
Apr-02-24 07:30AM	Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team (PR Newswire)
Mar-21-24 10:46AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 08:53PM	TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials (GuruFocus.com)
04:05PM	Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates (PR Newswire)
Mar-13-24 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024 (PR Newswire) +5.39%
Feb-28-24 07:30AM	Trevi Therapeutics to Participate in Upcoming March Events (PR Newswire) +5.78%
Feb-06-24 07:30AM	Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-17-24 12:00PM	Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-04-24 07:30AM	Trevi Therapeutics Provides Business Updates (PR Newswire) +5.34%
Dec-05-23 07:30AM	Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) (PR Newswire)
Nov-30-23 09:35AM	Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI) (Zacks)
Nov-14-23 09:55AM	Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) +6.72%
09:35AM	After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI) (Zacks)
Nov-12-23 11:13AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-02-23 07:30AM	Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio for Refractory Chronic Cough (PR Newswire) -5.68%
Nov-01-23 04:05PM	Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023 (PR Newswire)
Oct-13-23 08:30AM	Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio in Prurigo Nodularis (PR Newswire)
Oct-11-23 12:00PM	Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-06-23 07:30AM	Trevi Therapeutics to Participate in Upcoming September Events (PR Newswire)
Aug-12-23 08:30AM	Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-11-23 06:44AM	Q2 2023 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:05PM	Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-03-23 04:05PM	Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023 (PR Newswire)
Aug-01-23 07:30AM	Trevi Therapeutics to Participate in Upcoming August Events (PR Newswire)
Jul-06-23 07:30AM	Trevi Therapeutics to Participate in Upcoming July Investor Events (PR Newswire)
Jun-04-23 10:45AM	Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) top owners are private equity firms with 35% stake, while 32% is held by hedge funds (Simply Wall St.)
May-30-23 07:30AM	Trevi Therapeutics to Participate in Upcoming June Conferences (PR Newswire) -14.81%
May-22-23 04:05PM	Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence (PR Newswire) -5.00% +5.26%
May-16-23 11:46AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 06:38AM	Q1 2023 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.67%
May-11-23 04:05PM	Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-10-23 08:48AM	Is a Surprise Coming for Trevi Therapeutics (TRVI) This Earnings Season? (Zacks)
May-09-23 07:30AM	Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023 (PR Newswire)
May-04-23 04:05PM	Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 (PR Newswire)
May-02-23 07:30AM	Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference (PR Newswire)
Apr-27-23 07:30AM	Trevi Therapeutics to Participate in Upcoming May Investor Events (PR Newswire)
Apr-11-23 04:05PM	Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-18-23 02:03AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 06:19AM	Q4 2022 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 04:05PM	Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update (PR Newswire)
Mar-09-23 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023 (PR Newswire) -9.22% -14.21%
Mar-08-23 07:30AM	Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
Mar-06-23 04:05PM	Trevi Therapeutics to Participate in Upcoming March Conferences (PR Newswire) -5.46%
Feb-21-23 07:00AM	Presenting on the Emerging Growth Conference on February 22 Register Now (GlobeNewswire) -10.73%
Feb-16-23 07:30AM	Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 (PR Newswire)
Feb-02-23 07:30AM	Trevi Therapeutics to Present and Participate in Upcoming February Conferences (PR Newswire) +20.17%
Jan-25-23 09:00AM	Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast (Newsfile)
Jan-05-23 04:05PM	Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences (PR Newswire) +8.49%
Dec-26-22 08:26AM	Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) stock price dropped 13% last week; private equity firms would not be happy (Simply Wall St.)
Dec-19-22 04:05PM	Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference (PR Newswire) -7.28%
Nov-14-22 04:05PM	Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer (PR Newswire) +8.91%
Nov-10-22 04:05PM	Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Nov-08-22 07:30AM	Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference (PR Newswire)
Nov-03-22 04:05PM	Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022 (PR Newswire)
Oct-27-22 07:30AM	Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting (PR Newswire)
Sep-30-22 09:40AM	Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-23-22 01:18AM	/C O R R E C T I O N -- Trevi Therapeutics, Inc./ (PR Newswire) -9.56%
Sep-22-22 04:01PM	Trevi Therapeutics Announces Proposed Public Offering (PR Newswire) -12.24%
Sep-19-22 09:35AM	Trevi Therapeutics Shares Jump After Complete Data From Chronic Cough Trial (Benzinga) -6.13%
07:30AM	Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
Sep-14-22 09:40AM	Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year? (Zacks)
Sep-07-22 07:30AM	Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-30-22 04:05PM	Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022 (PR Newswire) -9.50%
Aug-24-22 07:30AM	Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release (PR Newswire)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOOD JENNIFER L	President & CEO	Sep 06 '24	Option Exercise	1.43	4,219	6,033	217,532	Sep 09 05:00 PM
GOOD JENNIFER L	President & CEO	Sep 09 '24	Option Exercise	1.43	1,840	2,631	215,153	Sep 09 05:00 PM
GOOD JENNIFER L	President & CEO	Sep 06 '24	Sale	3.03	4,219	12,784	213,313	Sep 09 05:00 PM
GOOD JENNIFER L	President & CEO	Sep 09 '24	Sale	3.04	1,840	5,587	213,313	Sep 09 05:00 PM
GOOD JENNIFER L	President & CEO	Sep 05 '24	Option Exercise	1.43	40,277	57,596	253,590	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 04 '24	Option Exercise	1.43	10,981	15,703	224,294	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 03 '24	Option Exercise	1.43	3,863	5,524	217,176	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 05 '24	Sale	3.11	40,277	125,310	213,313	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 04 '24	Sale	3.02	10,981	33,205	213,313	Sep 05 04:54 PM
GOOD JENNIFER L	President & CEO	Sep 03 '24	Sale	3.02	3,863	11,677	213,313	Sep 05 04:54 PM
GOOD JENNIFER L	Officer	Sep 03 '24	Proposed Sale	3.16	61,180	193,328		Sep 03 04:37 PM
Meeker David P	Director	Aug 27 '24	Option Exercise	1.43	4,555	6,514	357,044	Aug 29 04:55 PM
Meeker David P	Director	Aug 27 '24	Sale	2.93	4,555	13,353	352,489	Aug 29 04:55 PM
Meeker David P	Officer	Aug 27 '24	Proposed Sale	2.98	4,555	13,573		Aug 27 04:10 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 19 '24	Option Exercise	1.43	16,496	23,589	236,811	Aug 21 04:00 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 19 '24	Sale	2.96	16,496	48,883	220,315	Aug 21 04:00 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 16 '24	Option Exercise	1.43	18,660	26,684	238,975	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 15 '24	Option Exercise	1.43	12,745	18,225	233,060	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 14 '24	Option Exercise	1.43	100	143	220,415	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 16 '24	Sale	2.76	18,660	51,440	220,315	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 15 '24	Sale	2.79	12,745	35,513	220,315	Aug 16 04:47 PM
SCIASCIA THOMAS	Chief Scientific Officer	Aug 14 '24	Sale	2.75	100	275	220,315	Aug 16 04:47 PM
SCIASCIA THOMAS	Officer	Aug 15 '24	Proposed Sale	2.61	48,001	125,282		Aug 15 04:23 PM
SCIASCIA THOMAS	Chief Scientific Officer	May 29 '24	Option Exercise	2.19	59,354	129,985	267,801	May 31 04:07 PM
SCIASCIA THOMAS	Chief Scientific Officer	May 29 '24	Sale	2.55	53,368	136,110	214,433	May 31 04:07 PM
Delfini Lisa	Chief Financial Officer	May 22 '24	Option Exercise	0.51	16,043	8,198	57,629	May 24 04:12 PM
Delfini Lisa	Chief Financial Officer	May 22 '24	Sale	2.64	4,350	11,485	53,279	May 24 04:12 PM
GOOD JENNIFER L	President & CEO	May 20 '24	Option Exercise	2.19	25,037	54,831	238,350	May 22 04:30 PM
GOOD JENNIFER L	President & CEO	May 20 '24	Sale	2.86	25,037	71,576	213,313	May 22 04:30 PM
GOOD JENNIFER L	President & CEO	May 10 '24	Option Exercise	2.19	4,578	10,026	217,891	May 14 04:51 PM
GOOD JENNIFER L	President & CEO	May 10 '24	Sale	2.90	4,578	13,276	213,313	May 14 04:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRVI

Trevi Therapeutics Inc

Upgrade your FINVIZ experience